Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment

AIDS

Volumn 12, Issue 17, 1998, Pages 2313-2320

  Chêne, Geneviève ^a,b   Binquet, Christine ^a   Moreau, Jean François ^b   Neau, Didier ^b   Pellegrin, Isabelle ^c   Malvy, Denis ^b   Ceccaldi, Joël ^d   Lacoste, Denis ^b   Dabis, François ^a  

^a INSERM   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d Centre Hospitalier de Libourne   (France)

Author keywords

Cohort study; Disease progression; HIV infection; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HEMOGLOBIN; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; COHORT ANALYSIS; DEATH; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 0032480992     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199817000-00013     Document Type: Article

References (31)

1. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
2. Gulick R, Mellors J, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
3. Collier AC, Coombs RW, Schoenfeld DA, Bassett R, Baruch A, Corey L: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996, 334:1011-1017.
4. Powderly W, Sension M, Conant M, Stein A, Clendeninn N: The efficacy of viracept (nelfinavir mesylate, NFV) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 132].
5. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
6. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
7. Jacobson MA, Zegans M, Pavan PR, et al.: Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997, 349:1443-1449.
8. Connors M, Kovacs JA, Krevat S, et al.: HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997, 3:533-540.
9. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
10. Marimoutou C, Chêne G, Dabis F, Lacoste D, Salamon R, for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine: HIV infection and AIDS in Aquitaine. Data obtained over the last ten years with a hospital-based information system, 1985-1995 [in French]. Presse Med 1997, 26:703-710.
11. Dormont I, Brun-Vézinet F: Modalités de prescription de la mesure de la charge virale (ARN VIH plasmatique) chez les personnes atteintes par le VIH et ses conséquences en matière de suivi et de stratégie thérapeutique. Paris: Ed. Flammarion Médecine Sciences; 1996:26.
12. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:1-19.
13. Kaplan EL, Meier P: Non parametric estimation from incomplete samples. J Am Stat Assoc 1958, 53:457-481.
14. Cox DR: Regression models and life table. J R Stat Soc (B) 1972, 34:187-200.
15. Collett D: Modelling Survival Data in Medical Research. London: Chapman & Hall; 1994:347.
16. Hoover DR, Graham NMH, Chen B, et al.: Effect of CD4+ cell count measurement variability on staging HIV-1 infection. J Acquir Immune Defic Syndr 1992, 5:794-802.
17. Kaufmann D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998, 351:723-724.
18. Downs AM, Heisterkamp SH, Brunet JB, Hamers FF: Reconstruction and prediction of the HIV/AIDS epidemic among adults in the European Union and in the low prevalence countries of central and eastern Europe. AIDS 1997, 11:649-662.
19. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD, for the VA Cooperative Study Group on AIDS: Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997, 126:939-945.
20. Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
21. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
22. BHIVA Guidelines Co-ordinating Committee: British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
23. Ehmann CW, Eyster ME, Wilson SE, Andes WA, Goedert JJ, for the Multicenter Hemophilia Cohort Study: Relationship of CD4 lymphocyte counts to survival in a cohort of hemophiliacs infected with HIV: Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994, 7:1095-1098.
24. Neumann AU, Gorochov G: HIV antivirals and immune recovery. Nat Med 1997, 3:703-704.
25. Tural C, Romeu I, Andreu D, et al.: Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998, 177:1080-1083.
26. Kaplan JE, Masur H, Jaffe HW, Holmes KK: Preventing opportunistic infections in persons infected with HIV: 1997 guidelines. JAMA 1997, 278:337-338.
27. DeGruttola V, Wulfsohn M, Fischl MA, Isiatis A: Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993, 6:359-365.
28. Choi S, Lagakos SW, Schooley RT, Volberding PA: CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993, 118:674-680.
29. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocytes counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
30. Hughes MD, Johnson VA, Hirsch MS, et al.: Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997, 126:929-938.
31. Lagakos SW: Surrogate markers in AIDS trials: conceptual basis, validation, and uncertainties. Clin Infect Dis 1993, 16 (suppl 1):S22-S25.